PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

(2010) P. G. Maslak et al.   BLOOD

PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal

(2010) Shreya Kanodia et al.   PLoS One

The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It?

(2010) Bing Z. Carter et al.   SEMINARS IN HEMATOLOGY

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

(2009) U. Keilholz et al.   BLOOD

High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow

(2008) J. J. Melenhorst et al.   BLOOD

A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease

(2008) P G Maslak et al.   LEUKEMIA

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy

(2008) A S M Yong et al.   LEUKEMIA